Sporos is transforming knowledge into new hope for patients with cancer and immune diseases. Harnessing our vast network, strategic resources, and operational expertise, the Sporos team of highly accomplished leaders identifies novel disease mechanisms and catalyzes the development of breakthrough medicines.



With a mix of impressive scientific expertise and operational understanding of the biotech industry, as well as deep roots in the burgeoning Houston biotech ecosystem, the Sporos leadership team is uniquely positioned to identify and advance a growing pipeline of first-in-class treatment options.



We are advancing a pipeline of breakthrough therapies diversified across four entities with a focus on cancer and serious immune disease. Through our vast network of scientific experts, we aim to identify first-in-class therapeutic approaches with the potential for significant patient impact.

Clinical stage company focused on breakthrough medicines for cancer, inflammation, and fibrosis.

Development stage company focused on novel immune regulatory antibody therapeutics for cancer and autoimmune and infectious diseases.

Pioneering the discovery and development of novel small molecule inhibitors targeting cellular transporters at the nexus of tumor metabolism and immunity.

Development stage company focused on novel therapies targeting factors produced by cancer-associated fibroblasts, critical for tumor growth.


Recent News

View the latest news and press releases from Sporos Bioventures

Sporos Launches with $38.1 Million Series A Financing

Company intends to develop and extend its diverse pipeline of therapies for cancer and immune diseases, beginning with …

Read More →

Nirogy Therapeutics to Present at AACR Annual Meeting 2021

E-posters highlighting preclinical data demonstrate the potential of Nirogy’s small molecule therapies to enable significant activation of anti-tumor …

Read More →

JLABS @ TMC and Asylia Therapeutics on Navigating a Powerful Tool: The Human Immune System

Houston: the true third coast of innovation. Texas is home to more than 5,400 life science R&D and …

Read More →

Nirogy Therapeutics Launches with $16.5 Million Series A Financing

Boston, Massachusetts.  January 26, 2021 – Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to …

Read More →
Scroll to Top